Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBIT (2016 - 2026)

Heron Therapeutics filings provide 15 years of EBIT readings, the most recent being -$4.8 million for Q1 2026.

  • On a quarterly basis, EBIT fell 251.08% to -$4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.5 million, a 192.42% decrease, with the full-year FY2025 number at -$2.5 million, up 77.98% from a year prior.
  • EBIT hit -$4.8 million in Q1 2026 for Heron Therapeutics, down from $38000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $4.2 million in Q4 2024 to a low of -$62.9 million in Q1 2022.
  • Median EBIT over the past 5 years was -$6.4 million (2024), compared with a mean of -$17.9 million.
  • Biggest five-year swings in EBIT: skyrocketed 165.74% in 2025 and later crashed 251.08% in 2026.
  • Heron Therapeutics' EBIT stood at -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then crashed by 99.09% to $38000.0 in 2025, then plummeted by 12639.47% to -$4.8 million in 2026.
  • The last three reported values for EBIT were -$4.8 million (Q1 2026), $38000.0 (Q4 2025), and -$4.1 million (Q3 2025) per Business Quant data.